Histrelin is a synthetic gonadotropin-releasing hormone agonist primarily prescribed to manage central precocious puberty in children and advanced prostate cancer in men by suppressing luteinizing hormone… Read more
Histrelin is a synthetic gonadotropin-releasing hormone agonist primarily prescribed to manage central precocious puberty in children and advanced prostate cancer in men by suppressing luteinizing hormone and follicle-stimulating hormone secretion. The following category provides high-quality reference standards essential for rigorous analytical testing and pharmaceutical quality control protocols. These materials, including Histrelin active pharmaceutical ingredient, associated process-related impurities, and stable isotope labelled compounds such as Histrelin-d7 trifluoroacetate, serve as critical tools for method development and validation. Laboratories rely on these reference compounds to facilitate accurate impurity profiling, verify the purity of drug substances, and enable the precise quantification of potential degradation products during stability studies. Utilizing consistent standards ensures compliance with regulatory requirements and supports the reliable assessment of therapeutic efficacy and safety throughout the pharmaceutical product lifecycle.